Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > Antiretroviral Drugs > Flashcards

Antiretroviral Drugs Flashcards

1
Q

Nucleoside/-tide Reverse Transcritpase Inhibitors (NRTIs)

A 
"Lam Did Stav Ten Zebras while Eating Aba's NRTIs"
Abacavir
Didanosine 
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

A

“REN”

Rilpivirine, Efavirenz, Nevirapine,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Protease Inhibitors

A 
..NAVIR
Atazanavir
Darunavir
Indinavir
Lopinavir
Nelfinavir
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Entry Inhibitors

A

“MEn enter”

Enfuviritde, Maraviroc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Integrase Inhibitor

A

“RED”

Dolutegravir, Elvitegravir, Raltegravir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pharmacokinetic enhancers

A

Cobicistat

Ritonavir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

NRTIs

MOA

A

Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

MOA: analogs of native ribosides (lack 3’OH)

  • Phosphorylated by cellular enzyme and incorporated into viral DNA by reverse transcriptase
  • Lack of 3’OH terminates DNA elongation ie. they are competitive inhibitors of reverse transcriptase
  • Most have activity against HIV 2 (africa) as well as HIV 1 (Western world)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NRTIs AE

A

> 1 NRTI causes toxicities to overlap

AE mainly due to inhibition of mitochondrial DNA polymerase: peripheral neuropathy, myopathy, lipoatrophy and lactic acidosis

Pancreatitis, myelosuppression and cardiomyopathy can also occur

Liver toxicity is rare but fatal (lactic acidosis, hepatomegaly with steatosis)

Zidovudine and stavudine may be particularly associated with dyslipidemia and insulin resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

NRTIs DI

Didansosine and Tenofovir

A

Tenofovir increases plasma didanosine levels ~ 60%.
doses of didansosine have to be reduced

NRTIs are not metabolized by cytochrome enzymes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Zidovudine (ZDV, AZT)
Nucleoside analog:
Pharmacokinetics:

A

Nucleoside Analog : Thymidine

Pharmacokinetics

  • Oral
  • Penetrates well across BBB
  • Dosage adjustments required patients w/ cirrhosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Zidovudine (ZDV, AZT) AE:

CI:

A

AE:
Bone marrow suppression (neutropenia, anemia)
GI intolerance, headaches, insomnia

CI:
- Toxicity potentiated by coadmin. of probenecid, acetaminophen, lorazepam, indomethacin and cimetidine. (PLACI)

  • Stavudine and ribavirin activated by same pathways (might reduce active levels of zidovudine)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Stavudine (d4T): MOA/PK

what does it have high affinity for?

A

Strong inhibitor of beta and gama DNA polymerases (high affinity for mitochondrial DNA polymerase, which can lead to toxicity)

Nucleoside Analog:
Thymidine

PK: Oral, dosage adjustment required in renal insufficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Stavudine AE

A

Peripheral neuropathy, lactic acidosis

Hyperlipidemia, neuromuscular weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Didanosine (DDL)

Analogue?

A

Adenosine analogue

PK: Absorption best taken in fasting state (acid labile) or combined with antacid.

  • penetrates into CSF
  • Dosage adjustment acquired in renal insufficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Didanosine (DDL) AE:

what does it have high affinity for?

A

High affinity for mitochondrial DNA polymerase
- Pancreatitis (esp. alcoholics and patients w/ hypertrigglyceridemia) - highest risk
Peripheral neuropathy, diarrheas, hepatic dysfunction
CNS effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Tenofovir (TDF)
Analog of?
Combos?

A

One of preferred NRTIs in currently recommended regimens

Nucleoside Analog
Adenosine

Fixed-dose combinations available
Tenofovir + emtricitabine
Tenofovir + emtricitabine + efavirenz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Tenofovir (TDF) PK/AE

A

PK: taken w/ food to increase bioavailability
- Long t1/2 (can dose once daily)

AE: GI (nausea, diarrhea, vomiting, flatulence)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Tenofovir (TDF) CI?

A

Serum creatinine monitored with renal insufficiency
Only NRTI with sig. drug interactions (increases didanosine concs. and dosage reductions are usually required)
- Decreases conc. of atazanavir (can be boosted with ritonavir.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q 
Lamivudine (3TC) MOA
what does it not affect?
ANALOG?
Resistance?
PK?
AE?
A

DOes not affect mitochondrial DNA synthesis or bone marrow precursor cells

CYTOSINE

High level of resistance with single amino substitutions.

dosage adjustment requirement w/ renal insufficiency

AE: Few significant (headache, dry mouth)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q 
Emtricitabine (FTC)
structurally related to?
ANALOG?
PK?
AE?
A

lamivudine
One of the prefered NRTIs in currently recommended regimens
Nucleoside analogue: Cytosine
PK: One a day admin.
AE: Hyperpigmentation of palms and soles (occurs most frequently in dark-skinned)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Abacavir (ABC)
ANALOG?
RESISTANCE?
AE?

A

Nucleotide analog:
Guanosine

Resistance:
- HIV resistance requires several mutations and tends to develop slowly.

AE: GI, headache, dizzinesss
- 5% - hypersensitivity reation (one or more of rash, GI, malaise, respiratory distress).

  • Sensitized individuals shoud NEVER be rechallenged!!!!! Can be genetically screened
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Non-Nucleoside Reverse transcriptase inhibitors (NNRTIs) MOA?

A

MOA

  • Highly selective, noncompetitive inhibitors of HIV 1 RT
  • Bind at distinct sites away from active sites (NNRTI pocket)
  • All NNRTIs bind within the same pocket
  • All result in inhibition of RNA and DNA dependent DNA polymerase.
  • DO NOT require phosphoryation by cellular enzyms***
23
Q

Advantages of NNRTIs

A

lack of effect on host blood-forming elements

lack of cross resistance with NRTIs (binding sites are distinct)

24
Q

Disadvantages of NNRTIs

A

Cross-resistance w/ NNRTIs
Drug interaction
HIGH incidence of hypersensitivity reactions (eg. rash)

25
Q

NNRTIs AE

A 
SKin rash (including stevens-johnson syndrome)
GI intolerance
ALL are CYP3A4 substrates and can act as inducers, inhibitors or both of CYPs.
26
Q

Nevirapine (NVP) Pharmacokinetics

AE?

A

excreted in urine as metabolites (CYP 3A4 and CYP 2B6)

AE: Potential severe hepatotoxicity ( DON’T use in women w/ CD4+ counts >250 and men >400)
RASH (16%), dermalogic effects (stevens johnson syndrome and toxic epiderml necrolysis)

14 day titration at 1/2 dose is mandatory to reduce risk of serrious epidermal reactions.

27
Q

Nevirapine (NVP)

what enzyme does it induce?

A

Inducer of CYP 3A4
Increases metabolism of PIs (no dosage adjustment necssary), oral contracpetives, Ketoconazole, methadone, metronidazole, quinidine, theophylline and warfarin).

28
Q

Efavirenz (EFV)
clinical appliations?
PK?

A

results in increased CD4+ counts and decreased viral load
Not a first line agent in new guidelines (2015)

PK:
Oral, t1/2 >40hrs (once a day dosing)
Extensively metabolized to inactive products

29
Q

Efavirenz (EFV) AE?

A

High rate of CNS toxicity (50%): dizziness, headache, vivid dreams, loss of concentration- possible association with suicidality.

RASH (25%)

Increased triglycerides, HDL and total cholesterol (lipid levels must be monitored at beginning of and during therapy).

30
Q

Efavirenz (EFV) CI:

A

Potent inhibitor of CYP 450 enzymes.

Pregnancy (D) (can be used after 1st trimester if considered best choice)

31
Q

Rilpivirine PK/AE

A

Oral, extensively metabolized to inactive products

AE: RASH, INSOMNIA, DEPRESSION, INCREASED Live enzymes!

32
Q

Protease Inhibitors (PIs) MOA

A

Reversible inhibitors of aspartyl protease of HIV
- inhibition prevents viral maturation and results in production of non-infectious virions!

DO NOT require intracellular activation
Active against both HIV-1 and HIV-2

33
Q

Protease Inhibitors (PIs) PK?

A

Poor oral bioavailability
High fat meals increase (nelfinavir) or decrease (indinabir) bioavailabilty
- Substrate for CYP 3A4 (most require enhancing w/ a PK enhancer).
- Substrates for P-glycoprotein pump
- Bound to plasma proteins (alpha1-acid glycoprotein which can increase in response to trauma and surgery).

34
Q

Protease Inhibitors AE

A

Parathesias, nausea, vomiting diarrhea

  • disturbances in lipid metabolism (diabetes, hypertriglycerodemia, hypercholesterolemia)
  • Chronic admin –> fat redistribution and accumulation resulting in central obesity, dorsocervical fat enlargement, peripheral and facial wasting, breat enlargement and a cushingoid appearance.***
35
Q

Protease Inhibitors DI:

A
  • Potent inhibitors and substrates of CYP isoforms:
    eg, rhabdomyolysis (simvastatin or lovastatin), excessive sedation (midazolam or triazolam), respiratory depression (fentanyl)
  • Warfarin, sildenafil and phenytoin require dosage adjustments
  • Rifampin and st. johns wort are CI.
36
Q

Entry/fusion inhibitors
Fusion inhibitor?
Entry inhibitor?

A

Fusion inhibitor:
- Emfuvirtide
Entry inhibitor
- Maraviroc

37
Q

Enfuvirtide (T-20)
whats special about Enfuvirtide
MOA?

A

• First approved drug that inhibits viral fusion
• Approved for use in treatment-experienced adults
with evidence of HIV replication**
• No activity against HIV-2

MOA
• Structurally similar to gp41 (HIV protein mediates
membrane fusion)

• Binds to GP41**subunit of the viral envelope glycoprotein,
preventing ability of virion to fuse cell membrane

38
Q

Enfutvirtide (T-20) PK/AE

A

Pharmacokinetics
• Parenteral admin. only

Adverse Effects
• Injection-related (3% discontinue)
• Hypersensitivity reactions & eosinophilia rarely
• No drug interactions with other antiretrovirals have
been noted

39
Q

MARAVIROC MOA

AE?

A

Binds specifically to CCR5**

Blocks HIV entry (only CCR5 tropic viruses can be treated with MARAVIROC doesnt work with CXCR4)

Well tolerated, risk of hepato toxicicity

Metabolized by CYP 3A4

40
Q

Integrase Strand Transfer Inhibitors (INSTI’s)

Clinical applications?

A

Clinical Applications Clinical Applications
• In combination with other antiretrovirals, INSTI’s are
approved for treatment-experienced and treatment-naive
patients with evidence of viral replication

• Currently most popular antiretroviral class due to good
side-effect profile and favorable effects on lipid
metabolism

41
Q

Dolutegravir PK?
AE
DI?

A

Pharmacokinetics
• Primarily eliminated by glucoronidatoin via UGT1A1
enzyme but some contribution from CYP 3A4.

Adverse Effects Adverse Effects
• Well tolerated (nausea, headache, diarrhea)
• Some reports of organ dysfunction (if so, discontinue
drug)

Drug Interactions
• Can occur due to CYP3A interactions

42
Q

Elvitegravir
PK?
AE?
DI?

A

Pharmacokinetics
• Primarily metabolized by CYP3A enzymes
• May require ‘enhancing’ with a PK enhancer (Cobicistat)

Adverse Effects
• Well tolerated ( nausea, headache, diarrhea)

Drug Interactions
• Can occur due to CYP interactions

43
Q

Raltegravir
Pk?
AE?
DI?

A

Pharmacokinetics
• Primarily eliminated by glucoronidation via UGT1A1
enzyme

Adverse Effects
• Well tolerated (nausea, headache, diarrhea)
• Can cause increases in creatine phosphokinases
DI i rug Interactions
• Rifampin, tipranavir & efavirenz may decrease [raltegravir]
• PPI’s may increase [raltegraivr]

44
Q

Pharmacokinetic enhancers

MOA?

A
  • Ritonavir (protease inhibitor)- never used a a protease inhibitor, mostly enhancer
  • Cobicistat
MOA
• Potent inhibitors of CYP 3A4
• Increase plasma concentrations of ARV allowing for
lower and/or less frequent dosing
• Improve tolerability of ARV
45
Q

Ritonavir

how is it used?

A

Used in combo with most protease inhibitors (NOT nelfinavir

Never used alone

46
Q

Cobicistat

A

Used commonly in combination with the INSTI elvitegravir

Also found in combo w/ darunavir and atazanavir

47
Q

Current recommendations for Tx-naive patients:

Regimens

A
  1. 2*NRTI + INSTI

2. 2*NRTI + PI

48
Q

Current recommendations for Tx-naive patients:

Selection based on:

A

• Avoiding the use of 2 agents of the same nucleotide
analog
• Avoiding overlapping toxicities and genotypic and
phenotypic characteristics of the virus
• Patient factors such as disease symptoms and concurrent
illnesses
• Impact of drug interactions; and
• Ease of adherence to a frequently complex administration
regimen

49
Q

Current recommendations for Tx-naive patients:

Prefered regimens

A

INSTI - based regimens

  1. Raltegravir + tenofovir + emtricitabine
  2. Dolutegravir + tenofovir + emtricitabine

PI-based regimen
1. Ritonavir-boosted darunavir + tenofovir + emticitabine

50
Q

Current recommendations for Infant born to HIV infected mother:

A

Zidovudine (start immediately after birth and administer for 6 weeks)

51
Q

HIV prophylaxis following a needle stick

A

Postexposure prophylaxis:

regimen containing atleast 3 antiretroviral drugs

Raltegravir + tenofovir + emtricitabine

for 28 days and can be stopped if source is shown to be HIV negative

52
Q

What Vaccines are recommeded for all HIV patients

A

Strep. Pneumoniae
Hep A
Hep B
Influenza

53
Q

What Vaccines are CI’d in HIV+ patients w/ CD4+ count

A 
Live vaccines eg,
MMR
Varicella and
Zoster
other vaccines may be administered w/out regard to the patients CD4+

Pharmacology (27 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions